Sequent post market hours yesterday said that the transaction contemplated under the share purchase agreement has been terminated.
Sequent Scientific is India's largest and amongst the ‘Top 20' global animal health companies, backed by global investment firm ‘The Carlyle Group' as promoter. The company has 8 manufacturing facilities across Europe, Turkey, Brazil & India with the Vizag site being India's only USFDA approved dedicated veterinary API facility.
The company reported a consolidated net loss of Rs 8.87 crore in Q3 FY23 as against a net profit of Rs 17.12 crore in Q3 FY22. Net sales rose 4.8% YoY to Rs 375.31 crore in Q3 FY23.